Trial Profile
A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2022
Price :
$35
*
At a glance
- Drugs Amantadine (Primary)
- Indications Movement disorders; Multiple sclerosis
- Focus Adverse reactions
- Acronyms INROADS3
- Sponsors Adamas Pharmaceuticals
- 09 Aug 2021 Status changed from active, no longer recruiting to completed.
- 15 Sep 2020 Planned End Date changed from 1 Jan 2021 to 1 Mar 2021.
- 15 Sep 2020 Planned primary completion date changed from 1 Aug 2020 to 1 Nov 2020.